7th Annual Live Medical Crossfire®: Hematologic Malignancies
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Addressing Clinical Gaps in Thyroid Cancer Management: Taking Action with Precision Methods to Personalize Treatment Decision-Making
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
Evolving Evidence in Pediatric Brain Cancer: Spotlight on MAPK Inhibitors
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical CancerJune 2nd 2023
Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.
Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast CancerJune 2nd 2023
Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.
EMA Committee Recommends Piflufolastat 18F PSMA PET Imaging Agent for Prostate CancerJune 1st 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of piflufolastat 18F, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent, for use in prostate cancer detection.
HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast CancerJune 1st 2023
Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.
Camidge and Weickhardt Consider Oncology Practice and Patient Care From an International PerspectiveJune 1st 2023
In this episode of How This Is Building Me, Drs Camidge and Weickhardt discuss the span of countries Dr Weickhardt’s medical training and career has led him to, the ins and outs of becoming a practicing oncologist in Australia vs the United States, and the importance of discerning patient needs and preferences to earn patient trust and deliver effective, personalized care across the globe.
Olverembatinib Recommended for Breakthrough Therapy Designation in China for SDH-Deficient GISTJune 1st 2023
The China National Medical Products Adminstration’s Center for Drug Evaluation has recommended that olverembatinib receive breakthrough therapy designation for the treatment of patients with gastrointestinal stromal tumor that is succinate dehydrogenase deficient.
Subcutaneous Pertuzumab/Trastuzumab Combo Continues to Prove Safe, Effective in HER2+ Breast CancerJune 1st 2023
Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer.
FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate CancerMay 31st 2023
The FDA has approved olaparib (Lynparza) plus abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.
Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status
Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.
Panitumumab Plus Trifluridine-Tipiracil Improves Outcomes in RAS Wild-type mCRCMay 31st 2023
The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.
Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer
Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.
Fox Chase Cancer Center’s Dr. Mary Daly Receives Inaugural Impact Award From Basser Center for BRCAMay 31st 2023
Fox Chase Cancer Center’s Mary Daly, MD, PhD, FACP was recently recognized as the first recipient of the BRCA Impact Award from Penn Medicine’s Basser Center for BRCA.
Epcoritamab Approval Introduces Novel Later-line Treatment Option in R/R DLBCLMay 31st 2023
Tycel Phillips, MD, discusses the significance of the FDA approval for epcoritamab in diffuse large B-cell lymphoma, key data from the EPCORE NHL-1 trial that support this approval, and how the approval of epcoritamab signals the expanding role of bispecific antibodies in this patient population.
Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin LymphomaMay 31st 2023
Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.
PARP Inhibitors Represent Effective Upfront Ovarian Cancer Treatment OptionsMay 31st 2023
Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.
Acclaim-1 Trial of Quaratusugene Ozeplasmid Plus Osimertinib in NSCLC Advances Into Phase 2 Expansion
The safety review committee for the phase 1/2 Acclaim-1 trial has ruled that the study evaluating quaratusugene ozeplasmid in combination with osimertinib in patients with advanced non–small cell lung cancer can proceed to the phase 2 expansion portion.
Improvements in Personalized Medicine Allow for Greater Exploration of Treatment De-escalation in Breast CancerMay 30th 2023
Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.
Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual MeetingMay 30th 2023
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.
FDA Grants Priority Review to Lifileucel in Advanced Melanoma
The FDA has granted priority review to the biologics license application for the tumor infiltrating lymphocyte therapy lifileucel for the treatment of patients with advanced melanoma who progressed on or after prior anti–PD-1/PD-L1 therapy and targeted therapy.